-epitope peptide and α galactocyl ceramide induces strong protective immunity against intracellular bacteria infection. Vaccine Congress Berlin 2005; New Approaches to Vaccine Development From the Bench to the Field. Berlin, Germany, September 8-10, 2005.

6. Koide Y, Hashimoto D, Uchijima M, Suda T, Chida K, Miyoshi H, Nagata T: Intratracheal administration of third-generation lentivirus vectors encoding MPT51 and Hsp65 from M. tuberculosis induces specific T cell responses in the lung. Vaccine Congress Berlin 2005; New Approaches to Vaccine Development From the Bench to the Field. Berlin, Germany, September 8-10, 2005.

7. 永田　年、小出幸夫：「ワクチン開発の新戦略」　細胞内寄生菌に対するCD8$^+$ T細胞誘導型ワクチン開発の戦略 第88回日本細菌学会関東支部総会、浜松、平成17年10月20日～21日

8. Koide Y, Nagata T, Uchijima M, Aoshi T, Shibata K: Intratracheal administration of a third-generation lentivirus vector encoding MPT51 from Mycobacterium tuberculosis induces specific T cell responses in the lung. 第35回日本免疫学会総会・学術集会. 横浜、2005（平成17年12月13～15日.

9. 永田　年、青枝大貴、鈴木美奈、内嶋雅人、柴田　清、小出幸夫: DNAワクチンを用いた結核菌分泌タンパクMPT51内HLA-A*0201拘束性CTLエピトープの同定. 第35回日本免疫学会総会・学術集会. 横浜、2005（平成17年12月13～15日）.

10. 内嶋雅人、永田　年、青枝大貴、柴田清、小出幸夫：結核菌に対するケモカイン・抗原結合型DNAワクチンの検討 第35回日本免疫学会総会・学術集会. 横浜、2005 （平成17年12月13～15日）

11. Hashimoto D, Uchijima M, Suda T, Chida K, Miyoshi H, Nagata T, Koide Y : Intratracheal administration of third-generation lentivirus vector encoding MPT51 from M. tuberculosis induces lung-homing specific T cells; Determinants of Host Resistance, Susceptibility or Immunopathology to Pathogens: Integrating Knowledge from Experimental Models to Human Disease, Keystone Symposia, Keystone, CO, USA, January 6 - 11, 2006

別紙4

研究成果の刊行に関する一覧表

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書　籍　名	出版社名	出版地	出版年	ページ
岡田全司	結核ワクチン	編集 泉孝英、 富岡洋海	結核　第4版	医学書院			2006 in press

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
岡田全司	Novel vaccines in Asia against Mycobacterium Tuberculosis and SARS.	Drug and Future			2006, in press
岡田全司	DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation.	Vaccine	24	1191-204	2006
岡田全司	Immunization with dendritic cells retrovirally transduced with mycobacterial antigen 85A gene elicits the specific cellular immunity including cytotoxic T-lymphocyte activity specific to an epitope on antigen 85A.	Vaccine	24	2110-9.	2006

岡田全司	Development of vaccines and passive immunotherapy against SARS corona virus using mouse and SCID-PBL/hu mouse models.	Xth International Nidovirus Symposium: Toward Control of SARS and Other Nidovirus Diseases			2006, in press
岡田全司	Novel recombinant BCG- and DNA-vaccination against tuberculosis in a cynomolgus monkey model.	Vaccine	23	2132-5	2005
岡田全司	The Development of vaccines against SARS Corona Virus in Mice and SCID-PBL/hu Mice.	Vaccine	23	2269-72	2005
岡田全司	Frontier of Mycobacterium Research - Host Vs Mycobacterium. "the 80th Annual Meeting Symposium	Kekkaku	80	613-629	2005
岡田全司	Novel vaccination (HVJ-liposome/HSP65 DNA + IL-12 DNA and recombinant 72f BCG) against tuberculosis using cynomolgus monkey.	40th Tuberculosis and Leprosy Research Conference US-JAPAN Cooperative Medical Science Program		46-50	2005
岡田全司	結核ワクチンの開発（抗酸菌感染症医療の進歩）	呼吸			2006, in press
岡田全司	結核：自然・獲得免疫と疾患「免疫と疾患」	最新医学	60	678-696	2005
岡田全司	結核ワクチン	呼吸器科	7	63-70	2005
菅原　勇	Pulmonary tuberculosis in various gene knockout mice with special emphasis on roles of cytokines and transcription factors.	Current Respiratory Medicine Review	1	Current Respiratory Medicine Review	2005
菅原　勇	The effects of inhalation of diesel exhausts on murine mycobacterial infection.	Exp. Lung Res	31	405-416	2005

菅原　勇	A reliable and reproducible method for evaluating cytokine and iNOS mRNA expression in guinea pig lung tissues by RT-PCR using newly designed primer sets.	Experimental Animals	54	163-172	2005
菅原　勇	Mycobacterium branderi isolated pus of a right pulmonary cavitary lesion.	Jap J Infect Dis	58	187−188	2005
菅原　勇	Temperature-mediated heteroduplex analysis for the detection of drug-resistant gene mutations in clinical isolates of Mycobacterium tuberculosis by denaturing HPLC and SURVEYOR nuclease.	Microbes and Infection	8	128-135	2006
菅原　勇	Diesel exhaust affects immunological action in the placentas of mice.	Environ Toxicol	20	431-440	2005
菅原　勇	Nude rat (F344/N-rnu) tuberculosis.	Cell. Microbiol			2005
菅原　勇	The molecular epidemiology of ethambutol-resistant M. tuberculosis in Henan province, China. Jpn.	J. Infect. Dis	58	393-395	2005
野内英樹	Rapid Awareness and Transmission of Severe Acute Respiratory Syndrome	American Journal of Tropical Medicine & Hygiene,	73(1)	17-25	2005
野内英樹	Characteristics of Voluntary Counseling and Testing (VCT) Acceptance among Pregnant Women Attending an Antenatal Care Clinic at Lerdsin Hospital,	The Journal of AIDS Research	7	131-140	2005

野内英樹	Identification of an Alternative 5'-untranslated Exon and new Polymorphisms of Angiotensin-converting Enzyme 2Gene: Lack of Association With SARS in the Vietnamese Population	Am J Med Genet	136(1)	52-57	2005
野内英樹	Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population.	Biochem Biophys Res Commun,	329(4)	1234-9	2005
服部俊夫	Low antibody response against tuberculous glycolipid(TBGL) in elderly gastrectomized tuberculosis patients.	The Int. J. Tb. Lung Dis.	9	1052-1053	2005
服部俊夫	Neutrophil survival-enhancing activity in sputum from patients with diffuse panbronchiolitis.	Respir. Med.	99	910-917	2005
服部俊夫	Cytokine-mediated xanthine oxidase upregulation in chronic obstructive pulmonary disease's airways.	Pulm. Pharmacol. Ther.	18	297-302	2005
高鳥毛敏雄	ドイツにおける一般対策の及びにくい人々に対する保健所活動.	公衆衛生	70(2)	106-109	2006
高鳥毛敏雄	英国リーズスタディツアー報告　英国公衆衛生制度改革	複十字	308	19-19	2006
高鳥毛敏雄	結核感染症の現状と今後の策	日本保険医学会誌	103(1)		2005
高鳥毛敏雄	英国、ロンドンで再興する結核とその対策	公衆衛生	69(3)	203-208	2005
高鳥毛敏雄	救急搬送要保護傷病入院患者の疾病構造と保健医療システムの現状の検討	社会医学研究	22	1-12	2005
高鳥毛敏雄	ホームレス者の健康・生活実態より健康権を考える－ホームレス者の生活習慣病対策からみた考察－	社会医学研究	22	41-50	2005

高鳥毛敏雄	アウト・リーチ活動により認められた路上・公園・河川敷等野宿生活者の健康実態と医療・保健・福祉制度の課題	社会医学研究	22	51-61	2005
赤川清子	Functional Heterogeneity of Colony-Stimulating Factor-Induced Human Monocyte-Derived Macrophages.	Respirology	11	S32-S36	2006
赤川清子	Catalase plays a critical role in the CSF-independent survival of human macrophages via regulation of the expression of Bcl-2 family genes.	J. Biol. Chem.	280	41137-41145	2005
阿部千代治	結核菌の薬剤耐性に関与する遺伝子	結核	80	804-807	2005
阿部千代治	結核菌薬剤感受性検査のためのBACTEC MGIT 960 ASTの評価：外部評価菌株を用いた研究	結核	81	57-62	2006
阿部千代治	Simple fibroblast-based assay to test the pyrazinamide susceptibility of Mycobacterium tuberculosis	Antimicrob Agents Chemother	49	804-807	2005
坂谷光則	DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation.	Vaccine.	2006 24	1191-1204	2005
坂谷光則	Development of vaccines and passive immunotherapy against SARS corona virus using mouse and SCID-PBL/hu mouse models. In "Xth International Nidovirus Symposium: Toward Control of SARS and Other Nidovirus Diseases" (Edit.) K. Holmes and S.	Perlman,			In press

坂谷光則	Incipient stage of pulmonary Langerhans-cell histiocytosis complicated with pulmonary tuberculosis was examined by high-resolution computed tomography.	Respir Med.	99(9)	1188-1190	2005
坂谷光則	The non-tuberculous mycobacteriosis.	Kekkaku.	80	25-30	2005
坂谷光則	Novel recombinant BCG- and DNA-vaccination against tuberculosis in a cynomolgus monkey model.	Vaccine	23	2132-2135	2005
坂谷光則	The Development of vaccines against SARS Corona Virus in Mice and SCID-PBL/hu Mice.	Vaccine	23	2269-2272	2005
坂谷光則	Novel vaccination (HVJ-liposome/Hsp65 DNA+ IL-12 DNA and recombinant 72f BCG) against Tuberculosis using cynomolgus monkey.	40th Tuberculosis and Leprosy Research Conference		46-50	2005
鈴木克洋	Rapid detection of Mycobacterium tuberculosis in respiratory samples by transcription - reverse ranscription concerted reaction with an automated system.	J. Clin.Microbiol	43	5435-5439	2005
鈴木克洋	肺カンサシ症の治療	結核	81	41-43	2006
鈴木克洋	肺結核を見落とさないために	呼吸と循環	54	63-69	2006
鈴木克洋	肺非結核性抗酸菌症は増加している：臨床からみた病原性と宿主要因の考察	最新医学	61	258-265	2006
鈴木克洋	質疑応答、肺MAC症の診断・治療.	日本医事新報	4225	90-91	2005
鈴木克洋	病気と薬の説明ガイド2005 肺結核	薬局	56（1）	899-905	2005
鈴木克洋	診療の秘訣「ツベルクリン反応の解釈」	Modern Physician			2005
鈴木克洋	私の処方「肺MAC症	Modern Physician	25	1596	2005
鈴木克洋	抗菌薬をつかいこなそう「結核」	メディチーナ			

竹田　潔	κBNS inhibits induction of a subset of Toll-like receptor-dependent genes and limits inflammation.	Immunity	24	41-51	2006
竹田　潔	Toll-like receptors 2 and 4 are differentially involved in Fas-dependent apoptosis in Peyers patch and liver at an early stage after bile duct ligation in mice.	Gut	5	105-113	2006
竹田　潔	The MyD88-dependent, but not the MyD88-independent, pathway of TLR4 signaling is important in clearing nontypeable haemophilus influenzae from the mouse lung.	J. Immunol	175	6042-6049	2005
竹田　潔	Essential function for the kinase TAK1 in innate and adaptive immune responses.	Nat. Immunol	6	1087-1095	2005
竹田　潔	Reduced prepulse inhibition of startle in STAT6-deficient mice.	Int. J. Mol. Med	16	73-675	2005
竹田　潔	Stat3 in resident macrophages as a repressor protein of inflammatory response.	J. Immunol	175	3354-3359	2005
竹田　潔	Cell type-specific involvement of RIG-I in antiviral response.	Immunity	23	19-28	2005
竹田　潔	Macrophage migration inhibitory factor contributes to the development of acute dextran sulphate sodium-induced colitis in Toll-like receptor 4 knockout mice.	Clin. Exp. Immunol	141	412-421	2005
竹田　潔	MyD88, but not Toll-like receptors 4 and 2, is required for efficient clearance of Brucella abortus.	Infect. Immun.	73	5137-5143	2005

竹田　潔	Muramyl dipeptide enhances osteoclast formation induced by lipopolysaccharide, IL-1β, and TNF-α through nucleotide-binding oligomerization domain 2-mediated signaling in osteoblasts.	Immunol	175	1956-1964	2005
竹田　潔	Priming effect of lipopolysaccharide on acetyl-coenzyme A: lyso-platelet-activating factor acetyltransferase is MyD88 and TRIF independent.	J. Immunol	175	1177-1183	2005
竹田　潔	IL-12p40 and IL-18 in crescentic glomerulonephritis: IL-12p40 is the key Th1-defining cytokine chain, whereas IL-18 promotes local inflammation and leukocyte recruitment.	J. Am. Soc. Nephrol	16	2023-2033	2005
竹田　潔	B lymphocyte activation by human papillomavirus-like particles directly induces Ig class switch recombination via TLR4-MyD88.	J. Immunol	174	7912-7919	2005
竹田　潔	Papillomavirus capsid mutation to escape dendritic cell-dependent innate immunity in cervical cancer.	J. Virol	79	6741-6750	2005
竹田　潔	PI3K integrates the action of insulin and leptin on hypothalamic neurons.	J. Clin. Invest	115	951-958	2005
竹田　潔	Down-regulation of dopamine transporter and abnormal behavior in STAT6-deficient mice.	Int. J. Mol. Med	15	819-825	2005
竹田　潔	Nonredundant roles of Sema4A in the immune system: Defective T cell priming and Th1/Th2 regulation in Sema4A-deficient mice.	Immunity	22	305-316	2005

竹田　潔	The nuclear IκB protein IκBNS selectively inhibits lipopolysaccharide-induced IL-6 production in macrophages of the colonic lamina propria.	J. Immunol	174	3650-3657	2005
竹田　潔	MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis.	J. Gastroenterol	40	16-23	2005
竹田　潔	Roles of Stat3 and ERK in G-CSF Signaling	Stem Cells	23	252-263	2005
竹田　潔	STAT6 deficiency inhibits tubulointerstitial fibrosis in obstructive nephropathy.	Int. J. Mol. Med	15	225-230	2005
竹田　潔	Differential roles of Toll-like receptors 2 and 4 in in vitro responses of macrophages to Legionella pneumophila.	Infect. Immun	73	352-361	2005
竹田　潔	The kinase domain of death-associated protein kinase is inhibitory for tubulointerstitial fibrosis in chronic obstructive nephropathy.	Int. J. Mol. Med.	15	73-78	2005
竹田　潔	Both IL-12 and IL-18 contribute to small intestinal Th1-type immunopathology following oral infection with Toxoplasma gondii but IL-12 is dominant over IL-18 in parasite control.	Eur. J. Immunol	34	3197-3207	2004
竹田　潔	In vivo transfection of a cis element 'decoy' against signal transducers and activators of transcription 6 (STAT6)-binding site ameliorates IgE-mediated late-phase reaction in an atopic dermatitis mouse model.	Gene Ther	11	1753-1762	2004

竹田　潔	In vivo transfection of a cis element 'decoy' against signal transducers and activators of the transcription 6 (STAT6) binding site ameliorates the response of contact hypersensitivity.	Gene Ther	11	1763-1771	2004
竹田　潔	Toll-like receptors and their adaptors in innate immunity.	Cur. Med. Chem	4	3-11	2005
竹田　潔	Toll-like receptors in innate immunity.	Int. Immunol	17	1-14	2005
竹田　潔	Evolution and integration of innate immune recognition systems: the Toll-like receptors.	J. Endotoxin Res	11	51-55	2005
竹田　潔	Mechanism for recognition of CpG DNA.	Vaccine Adjuvants		71-87	2005
吉田栄人	Robust salivary gland-specific transgene expression in Anophelesstephensi mosquito.	Insect Mol Biol			2006
吉田栄人	DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shockprotein 65 and interleukin-12 confers protection against Mycobacterium tuberculosis by T cell activation.	Vaccine	24	1191-1204	2006
吉田栄人	Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model.	Vaccine	23	2132-2135	2005
吉田栄人	The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice.	Vaccine	23	2269-2272	2005

松本　真	DNA augments antigenicity of mycobacterial DNA-binding protein 1 and confers protection against Mycobacterium tuberculosis infection in mice.	J Immunol	175(1)	441-449	2005
松本　真	Screening for Novel Antituberculosis Agents that are Effective Against Mutidrug Resistant Tuberculosis	Current Topics in Medicinal Chemistry			2006, in press
中島俊洋	Development of HVJ envelope vector and its application to gene therapy.	Adv Genet	53	07-332	2005
大原直也	Mutant Escherichia coli enterotoxin as a mucosal adjuvant causes specific CD4+ and CD8+ T cells to produce IFN・ and TNF・ inresponse to nasal killed-bacillus Catmette-Guerin vaccine in mice.	Vaccine			2006, in press
大原直也	A phospholipase C inhibitor suppresses amphotericin B-induced production of proinflammatory cytokines.	Microbiol. Immunol			2006, in press
大原直也	Hemoglobin receptor protein (HbR) of Porphyromonas gingivalis inhibits RANKL-induced osteoclastogenesis from bone marrow macrophages.	Infect. Immun			2006, in press
大原直也	Superoxide dismutase-encoding gene of the obligate anaerobe Porphyromonas gingivalis is regulated by the redox-sensing transcription activator OxyR.	Microbiology			2006, in press
大原直也	Dissecting the role of Rho-mediated signaling in contractile ring formation.	Mol. Biol. Cell	17	43-55	2006
大原直也	Porphyromonas gingivalis-induced platelet aggregation in plasma depends on Hgp44 adhesin but not Rgp proteinase.	Mol. Microbiol	59	152-167	2005

大原直也	Novel recombinant BCG and DNA-vaccination against tuberculosis in a cynomolgus monkey model.	Vaccine	23	2132-2135	2005
大原直也	Identification of a new membrane-associated protein which influences transport/maturation of gingipains and adhesions of Porphyromonas gingivalis.	J. Biol. Chem	280	668-8677	2005
大原直也	The novel stationary-phase-upregulated protein of Porphyromonas gingivalis influences the production of superoxide dismutase, thiol peroxidase and thioredoxin.	Microbiogy	151	841-853	2005
大原直也	ＢＣＧを用いた抗酸菌の抗原性および病原性に関する研究	日本細菌学雑誌	60	349-356	2005
倉島篤行	Rapid detection of Mycobacterium tuberculosis in respiratory samples by tran-scription-reverse transcription concerted reaction with an automated system.	J Clin Microbiol.	43	5435-39	2005
倉島篤行	肺癌と活動性肺抗酸菌症の混在する病態の検討。	結核	80	413-419	2005
倉島篤行	非結核性抗酸菌症の診断と治療	JIM	15	398-402	2005
倉島篤行	気密空間における感染性疾患	日本胸部臨床	64	325-332	2005
矢野郁也	Intact molecular characterization of cord factor (trehalose 6,6'-dimycolate)from nine species of mycobacteria by MALDI-TOF mass spectrometry.	Microbiology	151	3403-16	2005
矢野郁也	Clinical and prognostic importance of serotyping Mycobacterium avium-Mycobacterlum Intracellulare complex isolates in human immunodeficiency virus-negative patients.	J Clin Microbiol	43(7)	3150-8	2005

矢野郁也	Diverse humoral immune responses and changes in IgG antibody levels against mycobacterial lipid antigens in active tuberculosis.	Microbiology	151	2065-74	2005
矢野郁也	Direct molecular mass determination of trehalose monomycolate from 11 species of mycobacteria by MALDI-TOF mass spectrometry.	Microbiology	151	1443-52	2005
矢野郁也	Modified multiplex PCR for identification of Bacillus Calmette-Guerin substrain Tokyo among clinical isolates.	Vaccine	23(24)	3099-102	2005
矢野郁也	Bacillus calmette-guerin Tokyo172 substrain for superficial bladder cancer characterization and ant tumor effect.	J Urol	173(5)	1507-1	2005
矢野郁也	Serotype-specific modulation of human monocyte functions by glycopeptidol:pid(GPL) isolated from Mycobacterium avium complex.	Biol Pharm Bull	28(2)	335-9	2005
矢野郁也	Use of glycopeptidolipid core antigen for serodiagnosis of mycobacterium avium complex pulmonary disease in immunocompetent patients.	Clin Diagn Lab Imunol	12(1)	44-51	2005
小出幸夫	Immunization with gene encoding granulocyte-macrophage colony-stimulating factor inserted with a single helper T-cell epitope of an intracellular bacterium induces a specific T-cell subset and protective immunity.	Vaccine			2006, in press

小出幸夫	Immunization with dendritic cells retrovirally transduced with mycobacterial antigen 85A gene elicits the specific cellular immunity including cytotoxic T-lymphocyte activity specific to an epitope on antigen 85A.	Vaccine	24	2110-9.	2006
小出幸夫	Expression mapping by retroviral vector for $CD8^+$ T cell epitopes: definition of a Mycobacterium tuberculosis peptide presented by $H2\text{-}D^d$.	J Immunol Methods	298(1-2)	21-34	2005

ELSEVIER

Available online at www.sciencedirect.com
SCIENCE DIRECT

Vaccine 24 (2006) 1191–1204

Vaccine

www.elsevier.com/locate/vaccine

DNA vaccine using hemagglutinating virus of Japan-liposome encapsulating combination encoding mycobacterial heat shock protein 65 and interleukin-12 confers protection against *Mycobacterium tuberculosis* by T cell activation

Shigeto Yoshida[a,**], Takao Tanaka[b], Yoko Kita[b], Sachiko Kuwayama[b], Noriko Kanamaru[b], Yumiko Muraki[b], Satomi Hashimoto[b], Yoshikazu Inoue[b], Mitsunori Sakatani[b], Eiji Kobayashi[c], Yasufumi Kaneda[d], Masaji Okada[b,*]

[a] *Division of Medical Zoology, Department of Infection and Immunity, Jichi Medical School, Tochigi 329-0498, Japan*
[b] *Clinical Research Center, National Hospital Organization Kinki-chuo Chest Medical Center, Osaka 591-8555, Japan*
[c] *Division of Organ Replacement Research, Center for Molecular Medicine, Jichi Medical School, Tochigi 329-0498, Japan*
[d] *Division of Gene Therapy Science, Graduate School of Medicine, Osaka University, Osaka 565-0871, Japan*

Received 11 January 2005; received in revised form 24 August 2005; accepted 25 August 2005
Available online 19 September 2005

Abstract

We investigated the immunogenicity and protective efficacy of DNA vaccine combinations expressing mycobacterial heat shock protein 65 (Hsp65) and interleukin-12 (IL-12) using gene gun bombardment and the hemagglutinating virus of Japan (HVJ)-liposome method. A mouse IL-12 expression vector (mIL-12 DNA) encoding single-chain IL-12 proteins comprised of p40 and p35 subunits were constructed. In a mouse model, a single gene gun vaccination with the combination of Hsp65 DNA and mIL-12 DNA provided a remarkably high degree of protection against challenge with virulent *Mycobacterium tuberculosis*; bacterial numbers were 100-fold lower in the lungs compared to BCG-vaccinated mice. To explore the clinical use of the DNA vaccines, we evaluated HVJ-liposome encapsulated Hsp65 DNA and mIL-12DNA (Hsp65 + mIL-12/HVJ). The HVJ-liposome method improved the protective efficacy of the Hsp65 DNA vaccine compared to gene gun vaccination. Hsp65 + mIL-12/HVJ induced $CD8^+$ cytotoxic T lymphocyte activity against Hsp65 antigen. Most importantly, Hsp65 + mIL-12/HVJ vaccination resulted in a greater degree of protection than that evoked by BCG. This protective efficacy was associated with the emergence of IFN-γ-secreting T cells and activation of proliferative T cells and cytokines (IFN-γ and IL-2) production upon stimulation with Hsp65 and antigens from *M. tuberculosis*. These results suggest that Hsp65 + IL-12/HVJ could be a promising candidate for a new tuberculosis DNA vaccine, which is superior to BCG vaccine.
© 2005 Elsevier Ltd. All rights reserved.

Keywords: Tuberculosis; DNA vaccine; HVJ-liposome

1. Introduction

Tuberculosis is a major global threat to human health, with about 2 million people dying each year from *Mycobacterium tuberculosis* infections. The only tuberculosis vaccine currently available is an attenuated strain of *Mycobacterium bovis* BCG. BCG continues to be widely administered to children in developing countries, yet its efficacy remains controversial, particularly against the pulmonary form of the disease in adults. In recent years, the increasing frequency of drug-resistant *M. tuberculosis* isolates has further complicated the clinical management of this disease. Clearly, a more effective vaccine for the control of tuberculosis is urgently needed.

* Corresponding author. Tel.: +81 72 252 3021; fax: +81 72 251 1372.
** Corresponding author. Tel.: +81 285 58 7339; fax: +81 285 44 6489.
E-mail addresses: shigeto@jichi.ac.jp (S. Yoshida), okm@kch.hosp.go.jp (M. Okada).

0264-410X/$ – see front matter © 2005 Elsevier Ltd. All rights reserved.
doi:10.1016/j.vaccine.2005.08.103

It is well established that protective immunity to *M. tuberculosis* depends on both $CD4^+$ and $CD8^+$ T cells [1–6]. Because DNA vaccination results in the generation of cellular immune responses, including those of a Th-1-type response, and protection in animal models of infectious diseases [7,8]. In fact, several human clinical trials have recently been initiated to test the efficacy of DNA vaccines against emerging and re-emerging infectious diseases including hepatitis B [9], malaria [10,11] and HIV infections [12]. DNA vaccination has also shown potential for the development of tuberculosis vaccines in the mouse model [13–16]. However, in a guinea pig model, which is arguably one of the most biologically relevant systems available for studying human pulmonary tuberculosis, DNA vaccines has not proven more efficacious than BCG [17]. The efficacy of any experimental tuberculosis vaccine remains to be evaluated in human clinical trials and, thus, a vaccine against tuberculosis is still anxiously awaited.

Mycobacterial heat shock protein 65 (Hsp65) is a potential target for protective immunity and has been extensively studied [18]. Several groups have reported that *hsp65* DNA vaccines can induce strong protective immune responses in mice against virulent *M. tuberculosis* infections [19–21]. Protection is attributed to the establishment of a cellular immune response dominated by Hsp65-specific T cells that both produce IFN-γ and are cytotoxic towards infected cells. Furthermore, Lowrie et al. have reported that this vaccine reduces bacterial loads in mice infected with *M. tuberculosis* when given therapeutically after infection [22]. Interleukin-12 (IL-12) is a cytokine with a major role in the induction of IFN-γ-dominated immune responses to microbial pathogens. Orme and colleagues have demonstrated the importance of IL-12 in generation of the protective response to tuberculosis [23]. Co-administration of the IL-12 gene, which participates in the induction of IFN-γ dominated immune responses to microbial pathogens, with various tuberculosis DNA vaccines including the *hsp65* DNA [20,24] and 35 K MW DNA [25] may boost the efficacy of these DNA vaccines to levels achieved with BCG in the mouse model, although inhibitory effect rather than synergistic effect on immunotherapy was observed in mice co-administrated with *hsp65* DNA vaccine plus the *IL-12* gene.

In order to explore the preclinical use of tuberculosis DNA vaccine combinations of the *IL-12* DNA with the *hsp65* DNA, we chose the viral-based hybrid antigen delivery system hemagglutinating virus of Japan (HVJ)-liposome because this delivery system results in a high transfection efficacy, repeated gene transfection without reduction of gene transfer efficiency in vivo, and no apparent toxicity. These characteristics of HVJ-liposomes support the feasibility of its clinical application not only for cancer gene therapy but also for DNA vaccinations. In a recent study, highly efficient transfection of muscle cells was observed for several weeks when pcDNA3 plasmid containing the human tumor antigen genes, *MAGE-1* and *MAGE-3*, were encapsulated in HVJ-liposomes and injected intramuscularly into mice [26]. Effective induction of $CD4^+$ T cell responses by a hepatitis B core particle-based HIV vaccine was achieved by subcutaneous administration of HVJ-liposomes in mice [27]. HVJ-liposomes were also very effective as a mucosal vaccine against HIV infection [28]. Thus, it is likely that HVJ proteins may be responsible for inducing a robust immune response. No side effects from repetitive injections of HVJ-liposomes into mice, rats or monkeys were observed.

We designed this study to clarify the clinical feasibility of HVJ-liposome-mediated DNA vaccines for tuberculosis. First, we clarify that co-administration of IL-12 DNA with Hsp65 DNA via gene gun delivery enhanced protection in mice compared with Hsp65 DNA alone. Second, we show that vaccination with HVJ-liposome encapsulated Hsp65 DNA resulted in better protection than did gene gun vaccination. Third, we demonstrate that HVJ-liposome encapsulated Hsp65 DNA and IL-12 DNA induce enhanced protective immunity in the mouse model compared to that seen with BCG. This protective efficacy was associated with the emergence of IFN-γ-secreting T cells upon stimulation with Hsp65 and purified protein derivative. These results suggest that Hsp65 + IL-12/HVJ could be a promising candidate for a new tuberculosis DNA vaccine, which is superior to BCG vaccine. We also discuss in this paper the prospects of this HVJ-liposome-based DNA vaccine for testing in primate models [29] and, ultimately, in a clinical setting.

2. Materials and methods

2.1. Bacteria

M. tuberculosis strain H37Rv and *M. bovis* BCG Tokyo were kindly provided by Dr. I. Sugawara (JATA, Tokyo, Japan). *M. bovis* BCG Tokyo was maintained in synthetic Sauton medium (Wako Chemicals, Osaka, Japan). For the mouse infection studies, a single colony of *M. tuberculosis* H37Rv was grown in Middlebrook 7H9 (DIFCO Laboratories, Detroit, MI: lot 137971 XA MD) medium supplemented with albumin–dextrose complex and grown at 37 °C until approximately mid-log phase. Aliquots were stored at −80 °C and thawed at 10 days before use, grown to mid-log phase in 7H9 medium.

2.2. Reagents and antibodies

Purified protein derivative (PPD: lot T-3-4) was obtained from JAPAN BCG Co., Ltd. (Tokyo, Japan). Killed *M. tuberculosis* H37Ra (lot 13971XA) was obtained from DIFCO Laboratories. Fetal calf serum (FCS: lot AGC6341) was obtained from Hyclone (Logan, UT). Anti-L3T4, anti-Lyt2.2 monoclonal antibodies and anti-Thy1.2 antibody were kindly provided by Dr. K. Kuribayashi (Mie University, Tsu, Japan) and Dr. E. Nakayama (Okayama University, Okayama, Japan) [30].

2.3. Animals

Inbred and specific pathogen-free female BALB/c mice were purchased from Clea Japan Inc. (Tokyo, Japan). Mice were maintained in isolator cages, manipulated in laminar flow hoods and used between 8 and 10 weeks of age. Infected animals were housed in individual micro-isolator cages in a biosafety level (BL) 3 animal facility of the NHO Kinki-chuo Chest Medical Center.

2.4. Cell lines

COS-7 cells were kindly provided by Dr. H. Endoh (Jichi Medical School, Tochigi, Japan). COS-7 cells were maintained at 37 °C in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% FBS, 2 mM L-glutamine, and antibiotics. A mouse mastocytoma cell line (P815: DBA/2 origin) was kindly provided by Dr. C.S. Henney (Fred Hutchinson Cancer Research Center, Seattle) [31]. A mouse macrophage cell line (J774.1: BALB/c origin) was kindly provided by Dr. P. Ralph (Sloan Kettering Cancer Inst., New York, NY) [32]. The P815 and J774.1 cells were maintained in RPMI 1640 medium (Flow Laboratories, Inc., Mclean, VA) supplemented with 10% FCS, penicillin (100 U/ml), streptomycin (100 μg/ml) and 5×10^{-5} M 2-mercaptoethanol [33,34].

2.5. Plasmid construction

The *hsp65* gene was amplified from *M. tuberculosis* H37Rv genomic DNA by PCR using a set of primers, phsp65-F1 and phsp65-R1, and cloned into the *Bam*HI/*Not*I sites of pcDNA3.1 (+) (Invitrogen, San Diego, CA) to generate pcDNA-hsp65. pcDNA-hsp65 was designated as Hsp65 DNA in this text. For the construction of the *hsp65* gene fused with the mouse Igκ secretion signal sequence, the PCR product was cloned into the *Bam*HI/*Not*I sites of pcDNA-CS87 [35] to generate pcDNA-Ighsp65. pcDNA-Ighsp65 was designated as IgHsp65 DNA in this text. For the construction of the mouse IL-12 (mIL-12) *p40* and *p35* single-chain gene, the *mIL12p35*and *mIL12p40* genes were cloned from pcDNA-p40p35 [35] by PCR using sets of primers, pmIL12p35-F1 and pmIL12p35-R1, and pmIL12p40-F1 and pmIL12p40-R1, respectively, and cloned into pcDNA3.1 (+) to generate pcDNA-mIL12p40p35-F. pcDNA-mIL12p40p35-F was designated as mIL-12 DNA in this text. As a control, pcDNA-EGFP vector expressing the *EGFP* gene was used. Sequences of oligonucleotide primers used are available as request.

2.6. Protein production and antibody preparation

Recombinant Hsp65 (rHsp65) protein was expressed in *E. coli* BL21 (λDE3) and purified by affinity chromatography on Ni-NTA columns (Qiagen).

2.7. Transfection

DNA transfection of COS-7 cells was performed with the PolyFect Transfection Reagent (Qiagen) according to the manufacturer's instructions. After 24 h, supernatant and cells were harvested separately. Immunoprecipitation of cell lysates and supernatants with antibodies were performed as described previously [36]. Rat anti-mouse IL-12p70 (BD Biosciences Pharmingen, San Diego, CA) and mouse anti-rHsp65 polyclonal antibody were used for immunoprecipitation. For IL-12 bioassay, COS-7 cells (1×10^6 cells/plate) were plated into 60-mm cell culture plates and transfected with 2.5 μg of pcDNA 3.1, pcDNA-mIL12p40 + p35, or pcDNA-mIL12p40p35-F using the PolyFect Transfection Reagent. At 48 h after transfection, culture supernatants were collected and stored at −70 °C until use. Various volumes of the supernatants were added to the mouse spleen cells (2×10^6 cells/ml). Murine culture supernatants after 60 h incubation were collected and the level of mouse IFN-γ measured using sandwich ELISA kits (BD Opt EIA™ Set. BD Biosciences Pharmingen), according to manufacturer's instructions.

2.8. Vaccination

2.8.1. Gene gun vaccination

Gold particles coated with plasmid DNAs and their cartridges were prepared as described previously [35]. The abdomen was shaved and gold particles coated with plasmid DNA (1 μg plasmid DNA per shot) was delivered once into the abdomen using a Helios Gene gun (Nippon Bio-Rad Laboratory, Tokyo, Japan) at a helium discharge pressure of 300 psi. A separate group was vaccinated once subcutaneously with 1×10^6 colony-forming units (CFU) of *M. bovis* BCG Tokyo strain.

2.8.2. HVJ-liposome vaccination

HVJ-liposomes were prepared as described previously [37]. The HVJ–liposome complex was aliquoted with 10% DMSO and stored at −70 °C until use. HVJ-liposomes without plasmid DNA was used and designated as Empty/HVJ in this text. Groups of BALB/c mice were vaccinated three times at 3-week intervals with 100 μl of HVJ-liposome solution containing 50 μg of pcDNA-IgHsp65 and/or 50 μg of pcDNA-mIL12p40p35-F in the tibia both anterior muscles. A separate group was vaccinated once with 1×10^6 CFU *M. bovis* BCG Tokyo by subcutaneous injection at four different sites (left upper, right upper, left lower, right lower back) at the same time. HVJ-liposome DNA vaccines encapsulating pcDNA-IgHsp65, pcDNA-mIL12p40p35-F, or combination of pcDNA-IgHsp65 and pcDNA-mIL12p40p35-F was designated as IgHsp65/HVJ, mIL-12/HVJ, and IgHsp65 + mIL-12/HVJ, respectively, in this text.

2.9. Challenge infection of vaccinated animals and bacterial load determination

Mice were challenged by the intravenous route with 5×10^5 CFU of *M. tuberculosis* H37Rv 3 weeks after the third vaccination as described previously [38]. At 5 and 10 weeks after *M. tuberculosis* H37Rv challenge, the lungs, spleens, and livers were aseptically homogenized by using homogenizer in saline, and serial dilutions of the organ homogenates were plated on Ogawa agar (Kyokuto, Tokyo, Japan) or 7H11 Middlebrook agar (Kyokuto). Plates were sealed up and incubated at 37 °C and the number of CFU was counted 2 or 4 weeks later. Results are converted to $\log_{10}$ values and $\log_{10}$ [mean ± standard deviation (S.D.)] for CFU/organ/animal were calculated for each experimental group.

2.10. Histological analysis

The lungs were obtained from the mice, fixed with 10% buffered formalin, and embedded in paraffin. Each block was cut into 4 μm-thick sections and stained using hematoxylin and eosin. Semi-quantitative morphometric analysis of pathological slides was performed by our modified method of Dascher et al. [39] using a micrometer-attached microscope (Microphot-FXA, Nikon, Japan) [39,40]. The longer axis and minor axis of each granuloma in the field (×4 magnification) were measured. Longer axis to minor axis of each granuloma were multiplied and added up. Three random fields from each tissue section of mice and six random fields of guinea pigs were evaluated, and the average score of the fields was designated as the granuloma index ($\times 10^{-2}$ mm^2). This method for the evaluation of granuloma area is significantly correlated with the granuloma area by other scanning method of hematoxylin and eosin section.

2.11. Tuberculosis-specific cytotoxic test using ^{51}Cr release

Eight weeks after the final vaccination, CTL activity of spleen cells and mesenteric lymph node cells from vaccinated mice was assessed by using the ^{51}Cr-release assay. P815 mastocytoma cells, which have the same major histocompatibility complex (MHC) (H-2^d) as BALB/c mice, were transfected with pcDNA-hsp65 and used as Hsp65 protein-expressing target cells. J774.1 macrophage cells were pulsed with *M. tuberculosis* (killed H37Ra) for 24 h and used as target cells. A total of 2×10^6 cells/ml effector splenic cells were treated with anti-CD8 antibody, anti-CD4 antibody or anti-Thy1.2 antibody followed by complement as described above. ^{51}Cr release was assessed using the ^{51}Cr-release assay [31,33] at the effector:target (E:T) ratio of 50:1. Spontaneous lysis (with medium alone) and maximum lysis (^{51}Cr release after three cycles of freeze-thaw) were set up for background and targets.

Percent specific lysis was determined as:

$$\left[\frac{(\text{experimental release} - \text{spontaneous release})}{(\text{maximum release} - \text{spontaneous release})}\right] \times 100.$$

2.12. Proliferative responses of lymphocytes

Vaccinated mice were sacrificed immediately prior to challenge, and 1×10^5 single spleen cells were cultured in a 96-well flat bottom plate (Linbro) with rHsp65 protein (10 μg/ml) or PPD (20 μg/ml) for 60 h at 37 °C, and then pulsed with 1 μCi of [^{3}H]thymidine per well for the final 12 h of incubation [30]. Cells were harvested onto glass wool fiber filters, and [^{3}H]thymidine incorporation was measured using a Liquid Scintillation Counter LSC-6100 (ALOKA Co. Ltd., Tokyo, Japan).

2.13. Production of cytokines (IL-2 and IFN-γ)

Mouse cytokines were measured in quantitative ELISAs for IL-2 and IFN-γ as described previously [38]. Briefly, spleen cells from vaccinated mice were cultured at a concentration of 5×10^6 cells/ml in 200 μl of medium at various antigen concentrations. Culture supernatants were collected 48 h later and the levels of IFN-γ and IL-2 measured using sandwich ELISA kits (BD Opt EIA™), according to manufacturer's instructions.

2.14. ELISPOT assay

The spleens were removed aseptically from vaccinated mice three weeks after the third vaccination. Antigen-specific IFN-γ-producing cells were determined by ELISPOT as described previously [41]. Briefly, ELISPOT plates (MultiScreen IP Filtration plate MAIPS45; Millipore, Bedford, MA) were coated with anti-mouse IFN-γ MAb R4-6A2 (BD Biosciences Pharmingen). Spleen cells from vaccinated mice were suspended to 1×10^7 cells/ml (1×10^6 cells/well). In some experiments, the spleen cells from mice vaccinated with IgHsp65 + mIL-12/HVJ were pre-incubated with anti-CD8 antibody or anti-CD4 antibody (1:50 dilution) for 15 min at 4 °C and then incubated with rabbit complement (1:10 dilution) (Cedarlane, Hornby, Ont., Canada) for 45 min at 37 °C as described previously [30,33]. The cells were placed in five wells into antibody-coated wells, and rHsp65 protein (10 μg/ml) or PPD (10 μg/ml) was added to each well. After 20 h of incubation at 37 °C, cells were removed by washing the plates, and the site of cytokine secretions was detected using biotynylated anti-mouse IFN-γ MAb XMG1.2 (BD Biosciences Pharmingen) and streptavidin-alkaline phosphatase conjugate (BD Biosciences Pharmingen). The enzyme reaction was developed with BCIP-NBT substrate (Vector Laboratories, Inc., Burlingame, CA). Spot-forming cells (SFCs) were enumerated using KS ELISPOT system (Carl Zeiss, Hallbergmoos, Germany).

2.15. Statistical analysis

Tukey–Kramer's HSD tests were used to compare $\log_{10}$ value of CFU between groups following challenge and T cell responses between groups in ELISPOT assay. Student's *t* tests were performed to compare T cell responses between groups in T cell proliferation assay and granuloma formation between groups following challenge. A *P*-value of <0.05 was considered significant.

3. Results

3.1. In vitro expression of Hsp65 and IL-12

The DNA vaccines encoding mature and secreted forms of Hsp65 were constructed as Hsp65 DNA and IgHsp65 DNA, respectively. Hsp65 DNA contains the full-length *M. tuberculosis hsp65* gene. IgHsp65 DNA contains the full-length *M. tuberculosis hsp65* gene fused to the mouse Igκ signal sequence. Each construct is driven by CMV promoter and terminated at a bovine growth hormone polyadenylation sequence. Hsp65 DNA or IgHsp65 DNA was transfected into COS-7 cells and cell lysates and supernatants were analyzed for the *hsp65* gene expression. As shown in Fig. 1A, the mature form was detected as a single band in cell lysates (lane 2), whereas the secreted form was detected as a doublet band in cell lysates (lane 3). The doublet of slightly higher molecular weight than the mature form is most likely due to incomplete cleavage of the Igκ signal peptide in COS-7 cells because only a single band corresponding to the mature form was seen when HeLa cells or HepG2 cells were transfected with pcDNA-IgHsp65 (data not shown).

Based on the results of study reporting with high levels of IL-12 expression [42], we constructed a mouse IL-12 expression vector, mIL-12 DNA. The vector encodes mouse single-chain IL-12 protein comprised of p40 and p35 subunits linked by Gly_6Ser polypeptide linkers. As shown Fig. 1A, COS-7 cells transfected with mIL-12 DNA transiently expressed the mouse single-chain IL-12 protein with molecular weight of 80 kDa (lane 8). Quantitative analysis using ELISA showed that the COS-7 cells transfected with the mIL-12 DNA secreted four-fold higher levels of mIL-12p70 (125 ng/ml) than those transfected with from pcDNAmIL-12p40 + p35 (30 ng/ml), which previously constructed as a murine expression vector with IL-12 p40 and p35 expression cassettes in tandem array [35] (data not shown). Consistent with the mIL-12p70 expression level, the supernatant form the mIL-12 DNA transfectant cells induced 3.2-fold higher levels of IFN-γ from murine T lymphocytes than that from pcDNAmIL-12p40 + p35 transfectant cells (Fig. 1B). Thus, the mIL-12 DNA construct expresses biologically active IL-12, indicating that the single-chain IL-12 DNA is an effective DNA vaccine adjuvant capable of inducing primary Th-1 responses.

3.2. Evaluation of the best combination of Hsp65-based DNA vaccines with mIL-12 DNA for vaccine efficacy via gene gun

We compared the protective abilities of two versions of Hsp65-based DNA vaccine (Hsp65 DNA versus IgHsp65 DNA), and combinations with mIL-12 DNA (Hsp65 DNA versus Hsp65 DNA plus mIL-12 DNA, or IgHsp65 DNA versus IgHsp65 DNA plus mIL-12 DNA). Mice vaccinated with Hsp65 DNA, IgHsp65 DNA, and the combination with



Fig. 1. Expression and biological analysis of Hsp65 and mIL-12. (A) In vitro expression analysis of Hsp65 and mIL-12 from cells transiently transfected with DNA vaccines. COS-7 cells were transfected with EGFP DNA (lanes 1, 4 and 7), Hsp65 DNA (lanes 2 and 5), IgHsp65 DNA (lanes 3 and 6), and mILp40p35-F DNA (lane 8). Following metabolically labeling with [^{35}S]methionine, cell lysates (lanes 1, 2, 3, 7 and 8) and supernatants (lanes 4–6) were immunoprecipitated with mouse anti-Hsp65 polyclonal antibody (lanes 1–6) or rabbit anti-murine IL-12p70 antibody (lanes 7 and 8). (B) The biological activities of IL-12 expressed in transfected cell supernatants in vitro. Culture supernatants from COS-7 cells transfected with pcDNA3.1 (no insert empty vector), pcDNA-mIL12p40 + p35 or pcDNA-mIL12p40p35-F were added to the mouse spleen cells (2×10^6 cells/ml) at the final concentration of 4% (v/v) and incubated for 60 h. The levels of mouse IFN-γ were measured using sandwich ELISA kits as described in Section 2.